Oral Abstract Session: Melanoma/Skin Cancers Sunday, June 6, 2021; 8:00 AM–11:00 AM EDT 9501 Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma. KF Grossmann, M Othus, SP Patel, et al Take-Home Message The… Read more »